Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Canadian scientists trap gut microbe fuel to improve blood sugar and liver health July 30, 2025 Minimally invasive ablation effective for early-stage kidney cancers March 3, 2026 Electrical stimulation predicts recovery potential after acute nerve injuries September 13, 2025